Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Erivedge May Be The Gleevec Of Hedgehog Inhibitors

Executive Summary

FDA approval of Curis/Genentech’s hedgehog inhibitor Erivedge validates the class, but basal cell carcinoma is only the ante; cancers exploit hedgehog signaling in a variety of ways yet to be elucidated.

You may also be interested in...



Still Enriched By Partnership, Curis Faces Ongoing Risks In 2014

The Lexington, Mass.-based oncology specialist seeks to resume enrollment in a Phase I trial halted after a patient death, while a revenue-generating drug partnered with Genentech could soon have a new competitor.

To REMS Or Not To REMS? Erivedge Shows Division At FDA Over Oncology Risk Management

The review division and CDER senior staff supported approval of Genentech’s highly teratogenic, basal cell carcinoma treatment vismodegib without a Risk Evaluation and Mitigation Strategy, but the Division of Risk Management believed a communications plan should be carried out under a REMS for the first-in-class Hedgehog pathway inhibitor.

Roche Oncology Turns In A Third Quarter To Rival The Good Old Days

Roche put up improved sales figures reflecting a 9% increase in oncology sales so far in 2012 and elaborated on its plan for continued growth in the face of eventual generic competition.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS054191

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel